Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks IPOs and placings
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Craneware trading in line after first-half growth
(Sharecast News) - US healthcare software and service specialist Craneware reported an 8% increase in first-half revenue in its interim results on Monday, to $91.2m. The AIM-traded firm said adjusted EBITDA for the six months ended 31 December was ahead 8% year-on-year to $27.5m, while adjusted profit before tax saw an 8% increase to $17m.
Profit before tax was ahead 13% at $5.9m, while adjusted basic earnings per share experienced a 4% increase to 42.8 cents per share.
Annual recurring revenue (ARR) reached $171.4m, making for a 3% increase from $166.4m in the first six months of the 2023 financial year.
Craneware recorded robust cash conversion, with EBITDA conversion over the last 12 months reaching 91%, compared to 77% a year earlier.
The company reported cash reserves of $63.9m and total bank debt of $59.2m at period end.
On the operational front, Craneware noted a positive response to its recently-launched optimisation suites, which it said offered strategic solutions for healthcare market challenges.
Sales to both existing and new customers significantly increased, reflecting an improving market backdrop.
Customer retention remained strong at over 90%, while the partner programme, facilitated by the Trisus platform, contributed to revenue growth.
Craneware said it was continuing to invest in research and development and innovation to capitalise on market opportunities.
The Trisus platform now boasted nearly 200 million unique patient encounters, enhancing competitive strength and opening avenues for product enhancement and new development.
Looking ahead, Craneware anticipated a strengthening market backdrop with US healthcare and hospital customers refocusing on the future.
The company said it was confident in delivering results for the year in line with current consensus, and saw clear potential for growth acceleration in the near-term.
"Our growth in the first half of the year is tangible evidence of the return of healthcare providers' focus to their strategic priorities and their increasing investment in technology to provide the insights to achieve them," said chief executive officer Keith Neilson.
"Through our investments in the Trisus platform, Craneware is well positioned to support our customers in this transformation of the business of US healthcare, providing us with a sizable opportunity and growth lasting for the long term."
Neilson said the company entered the second half of the year with good sales momentum and focus.
"We remain confident in the delivery of results for the year in line with current consensus, further growth acceleration over the near term, and our ability to create further long-term value for all stakeholders."
At 1115 GMT, shares in Craneware were down 0.24% at 2,105p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.